TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31662801
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide extended release (TA-ER) 32 mg into each knee (total 64 mg)
Study: 31662801
Drug: Traditional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional triamcinolone acetonide crystalline suspension (TAcs) 40 mg into each knee (total 80 mg)
Study: 31663465
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg + methotrexate
Study: 31663906
Drug: Wireless motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless motility capsules (WMC)
Study: 31665141
Drug: Heat-stable toxin-based
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable toxin-based vaccine candidates, dosage and duration not specified
Study: 31665349
Drug: Graded IV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded IV glucose infusion
Study: 31666082
Drug: Subcutaneous EEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous EEG
Study: 31666237
Drug: naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 750 mg immediately then 250 mg every 8 hours for 7 days
Study: 31666237
Drug: low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose colchicine 500 mcg three times per day for 4 days
Study: 31667659
Drug: Olaparib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (100 mg bid) + Carboplatin (AUC 4)
Study: 31667696
Drug: Conventional-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose oseltamivir (75 mg for adolescents/adults; 30-75 mg by body weight for children), twice daily for 10 days
Study: 31667696
Drug: Double-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose oseltamivir (150 mg for adolescents/adults; 60-150 mg for children), twice daily for 10 days
Study: 31667696
Drug: Conventional-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose oseltamivir
Study: 31667696
Drug: Double-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose oseltamivir
Study: 31668348
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (ferritin <100 μg L)
Study: 31668516
Drug: Patient decision
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD)
Study: 31668825
Drug: Geriatric assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric assessment (GA) administered prior to induction and prior to post-remission therapy
Study: 31668830
Drug: THC (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (15 mg oral)
Study: 31669155
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only)
Study: 31670288
Drug: Phosphorus-32 microparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus-32 microparticles with EUS guidance in combination with gemcitabine ± nab-paclitaxel
Study: 31670431
Drug: Mobile phone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone-based reporting of health-related quality of life (HRQOL) using FACT-G
Study: 31671877
Drug: Dose Intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Intensive Rituximab and High-Dose Methylprednisolone
Study: 31672144
Drug: BSL ≥
Normalized name: Baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSL ≥ 11.1 mmol/L
Study: 31672144
Drug: BSL <
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BSL < 6.0 mmol/L or 6.0-11.1 mmol/L
Study: 31672148
Drug: PCSK9 quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 quartile I (< 136 ng/mL)
Study: 31672148
Drug: PCSK9 quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 quartile IV (> 266 ng/mL)
Study: 31672853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PIVKA-II and AFP
Study: 31673295
Drug: 100-µg vitamin
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-µg vitamin D for 3 months
Study: 31673393
Drug: USPIO (ferumoxytol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO (ferumoxytol, 4 mg/kg) infusion
Study: 31673415
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg subcutaneously once every 2 weeks
Study: 31673426
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) delivered to the target lesion with a cumulative dose of 114 Gy (equivalent dose in 2 Gy with an alpha to beta ratio of 2.6).
Study: 31675952
Drug: Capecitabine 850
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850 mg/m2, P.O. bid, days 1-14, and ziv-aflibercept 6 mg/kg I.V., day 1, of each 21-day cycle
Study: 31676359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA19-9 and CEA
Study: 31676359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA19-9 and CA-125
Study: 31676359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA19-9 and thrombospondin-2
Study: 31678771
Drug: Everolimus after
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus after hepatic arterial embolisation therapy (HAET)
Study: 31679129
Drug: New injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: New injectable treatment for T2DM
Study: 31679507
Drug: PAHEPI program
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAHEPI program (Treatment 1)
Study: 31679507
Drug: PAHEPI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAHEPI + school meals (Treatment 2)
Study: 31682550
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal
Study: 31684094
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) intravenous furosemide (greater than 125 mg)
Study: 31684094
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) intravenous furosemide (less than 125 mg)
Study: 31684877
Drug: Anesthesia induction
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction with midazolam, sufentanil, and rocuronium, followed by sevoflurane, with positive pressure ventilation (PEEP 5, tidal volume 6-8 ml/kg)
Study: 31684927
Drug: Curcumin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (400 mg in enhanced absorption formulation)
Study: 31685467
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion (TCI) of cefepime, median duration of 4.5 days, targeting a blood concentration of 16 mg/liter
Study: 31685468
Drug: Telavancin; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin; specific dosage and duration not mentioned
Study: 31685476
Drug: Artefenomel and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel and DSM265 combination treatment
Study: 31685491
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine at doses 15 to 200 μg/kg every 3 weeks
Study: 31685491
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine at doses ≥120 μg/kg
Study: 31685491
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine (all doses)
Study: 31685491
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine at doses ≥150 μg/kg
Study: 31686036
Drug: Atezolizumab (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (neoadjuvant treatment)
Study: 31687203
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of Ranibizumab
Study: 31687203
Drug: 3 loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 loading doses of Ranibizumab
Study: 31688526
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further prolapse treatment
Study: 31689155
Drug: DSTP3086S (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTP3086S (2.4 mg/kg once every 3 weeks)
Study: 31689155
Drug: DSTP3086S (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTP3086S (doses > 2 mg/kg once every 3 weeks)
Study: 31689155
Drug: DSTP3086S (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTP3086S (weekly dosing)
Study: 31690286
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 100% oxygen at 2 atm absolute (ATA) for 90 minutes, 20 sessions for 5 days per week, followed by a second cycle of 20 sessions after 1 week of suspension.
Study: 31690697
Drug: Anti-FGFR3 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-FGFR3 antibodies positive patients (65 out of 426)
Study: 31690697
Drug: Anti-FGFR3 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-FGFR3 antibodies negative patients (361 out of 426)
Study: 31693389
Drug: Sound Production
Normalized name: IPM Wound Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound Production Treatment (SPT)
Study: 31693535
Drug: Nebivolol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol as monotherapy in de novo patients
Study: 31693535
Drug: Nebivolol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol as add-on therapy to existing antihypertensives
Study: 31694860
Drug: Dietary patterns
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary patterns of insulin pump users
Study: 31694860
Drug: Dietary patterns
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary patterns of multiple daily injection users
Study: 31695439
Drug: Single-use autoinjector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use autoinjector (AI) for benralizumab 30 mg
Study: 31697308
Drug: BMS-986156 monotherapy
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986156 monotherapy
Study: 31699157
Drug: Automated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated tablet audiometer
Study: 31699157
Drug: Tablet audiometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet audiometer for monosyllabic word recognition testing
Study: 31699157
Drug: Automated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated tablet audiometric evaluation
Study: 31699278
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with de novo heart failure undergoing reperfusion therapy
Study: 31699278
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with de novo heart failure undergoing reperfusion therapy
Study: 31699827
Drug: AZD4573 (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4573 (highly selective CDK9 inhibitor)
Study: 31700871
Drug: JS001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 at 10 mg/kg
Study: 31700871
Drug: JS001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 at 3 mg/kg
Study: 31700871
Drug: JS001 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 (all doses)
Study: 31700924
Drug: Taodan granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taodan granules (TDKL), administered twice per day, 7 days per week, for 8 weeks.
Study: 31700924
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice per day, 7 days per week, for 8 weeks.
Study: 31700924
Drug: Taodan granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taodan granules (TDKL) and Placebo, both administered twice per day, 7 days per week, for 8 weeks.
Study: 31701043
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) dressing (PICO™, Smith & Nephew, UK)
Study: 31701169
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose reduced to cumulative 60 Gy with simultaneous chemotherapy regimen of cisplatin 30 mg/m²
Study: 31701169
Drug: Standard multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multimodal treatments
Study: 31703570
Drug: Reconsolidation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconsolidation Therapy (RT) - involves recalling traumatic events with propranolol, once a week for 10-25 minutes over 6 weeks
Study: 31703637
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg followed by palliative radiotherapy with 5 × 4 Gray (Gy) = 20 Gy photon radiation (Group A)
Study: 31703728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eribulin (1.4 mg/m² daily) and everolimus (5 mg daily) at dose level A1
Study: 31703728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eribulin and everolimus at dose level A2
Study: 31703728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eribulin and everolimus at dose level B1
Study: 31703728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eribulin and everolimus
Study: 31703971
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of RCC
Study: 31704134
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on days 8 and 15 for cohorts 1 and 2.
Study: 31704214
Drug: Super-boosted lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-boosted lopinavir/ritonavir (LPV/r) 400/400 mg
Study: 31705425
Drug: Myocardial substrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myocardial substrate metabolism in BTHS
Study: 31706360
Drug: Swallowing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing and oral care (SOC) intervention
Study: 31707795
Drug: Canagliflozin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin, dosage and duration not specified
Study: 31707975
Drug: Ruxolitinib, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib, 20 mg orally twice daily for a 28-day cycle, continued for up to 16 cycles or until progressive disease or intolerability.
Study: 31708167
Drug: Veliparib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (250 mg BID) with chemotherapy (Regimen 1, continuous dosing)
Study: 31708167
Drug: Veliparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (400 mg BID) with chemotherapy (Regimen 1, intermittent dosing)
Study: 31708167
Drug: Veliparib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (150 mg BID) with weekly paclitaxel (Regimen 2, continuous dosing)
Study: 31708167
Drug: Veliparib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (250 mg BID) with weekly paclitaxel (Regimen 2, intermittent dosing)
Study: 31708167
Drug: Veliparib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (150 mg BID) with intraperitoneal chemotherapy (Regimen 3, continuous dosing)
Study: 31708167
Drug: Veliparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (400 mg BID) with intraperitoneal chemotherapy (Regimen 3, intermittent dosing)
Study: 31708167
Drug: Veliparib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (150 mg po BID) with chemotherapy (Regimens 1c, 2c, 2i, and 3c)
Study: 31708167
Drug: Veliparib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (250 mg po BID) with chemotherapy (Regimen 1i)
Study: 31708167
Drug: Veliparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (300 mg po BID) with chemotherapy (Regimen 3i)
Study: 31708167
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of continuous vs intermittent dosing of veliparib
Study: 31708296
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg for three courses)
Study: 31708810
Drug: ACCESS Integrated
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACCESS Integrated Care Model including Therapeutic Assertive Community Treatment
Study: 31709259
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (800 IU daily for 6 months)
Study: 31710189
Drug: Vaginal sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal sildenafil (suppository-100 mg/daily)
Study: 31710189
Drug: Vaginal placebo/sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal placebo/sildenafil (suppository-100 mg/daily)
Study: 31710189
Drug: Vaginal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal placebo (suppository)
Study: 31710684
Drug: Therapies and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies and side effects experienced by patients
Study: 31712075
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of pain with opioid analgesics
Study: 31712344
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy delay
Study: 31712349
Drug: Antineoplastic drugs
Normalized name: Platinum compounds, antineoplastic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplastic drugs (AD) exposure in nursing staff
Study: 31712813
Drug: Gentamicin 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 360 mg intramuscular dose
Study: 31713056
Drug: Structured daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured daily hip exercise regimen (extension and external rotation)
Study: 31714428
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of antiretroviral therapy use (particularly related to protease inhibitor use)
Study: 31719077
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of opioids with NSAIDs
Study: 31719077
Drug: 50% overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% overall reduction in opioid dosage, dose-extending placebos and NSAIDs
Study: 31720254
Drug: Flaxseed enriched
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed enriched yogurt (200 g 2.5% fat yogurt containing 30-g flaxseed)
Study: 31720293
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler, once daily for 24 weeks
Study: 31721017
Drug: Spebrutinib 375
Normalized name: Spebrutinib
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spebrutinib 375 mg/day
Study: 31721246
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) monotherapy withdrawal over ~6 months
Study: 31721246
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) monotherapy withdrawal
Study: 31721643
Drug: Atezolizumab 1,200
Normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1,200 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks
Study: 31722951
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy applied to craniomandibular structures, with four weekly sessions.
Study: 31723056
Drug: Labyrinth Devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labyrinth Devices Multichannel Vestibular Implant System vestibular implant
Study: 31723767
Drug: Idelalisib in
Normalized name: Product containing idelalisib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib in combination with Rituximab (IR)
Study: 31723767
Drug: Idelalisib in
Normalized name: Product containing idelalisib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib in combination with Bendamustine (IB)